Latest articles and price-sensitive announcements with AI sentiment classification.
The market no longer treats this ASX healthcare giant as flawless, and that may make the investment case more interesting. The post Why I'd buy CSL shares while sentiment is weak appeared first on The Motley Fool Australia.
Clever Culture Systems lands another big pharma client, with plasma big fish CSL ordering the company’s APAS Independence monitoring device ... Read More The post Clever Culture snags another big fish with CSL Behring client deal appeared first on Stockhead.
Is this beaten-down ASX healthcare giant finally turning a corner? The post Has the CSL share price finally bottomed out? appeared first on The Motley Fool Australia.
A Look At CSL (ASX:CSL) Valuation After Guidance Cut Impairments CEO Change And Share Price Rebound simplywall.st
How Investors Are Reacting To CSL (ASX:CSL) US$5b Vifor Impairment And Guidance Reset simplywall.st
CSL (ASX:CSL) Jumps 5.7% as Investors Pile Back Into Healthcare Stocks Down Under
CSL Shares Gain Some Ground Into The Weekend: The Latest Look thebull.com.au
CSL (ASX:CSL) Under Review: Why Shares Are up Today? Kalkine
These shares are having a strong finish to the week. But why? The post Why Chalice Mining, CSL, Megaport, and Pro Medicus shares are racing higher appeared first on The Motley Fool Australia.
CSL (ASX:CSL) Gains as Big-Cap Health Stocks Defy the Market Sell-Off Kalkine
CSL (ASX:CSL) Shares Under Pressure: Can the Healthcare Giant Rebuild Investor Confidence? Kalkine
Things went from bad to worse for this fallen giant last month. The post Why did CSL shares crash 22% in May? appeared first on The Motley Fool Australia.
These ASX healthcare shares may not regain investor confidence overnight, but I think they are worth studying while sentiment is weak. The post Are CSL and ResMed shares buys at 52-week lows? appeared first on The Motley Fool Australia.
It looks like brokers have lost confidence in one of these shares. The post WiseTech, Cochlear, CSL shares: Can these beaten down stocks rebound in 2026? appeared first on The Motley Fool Australia.
WiseTech, Cochlear, CSL shares: Can these beaten down stocks rebound in 2026? The Motley Fool Australia
CSL (ASX:CSL) Slips on ASX—Is This Just Pharma Volatility or Something Bigger? Kalkine
CSL's yield now rivals a big four bank... The post Historic: Here's why CSL shares are looking very interesting right now appeared first on The Motley Fool Australia.
Historic: Here's why CSL shares are looking very interesting right now The Motley Fool Australia
Highlights CSL continues to strengthen its healthcare footprint globally Defensive healthcare demand keeps investor interest active Growing focus on ASX dividend stocks supports sector visibility CSL remains one of the most recognised healthcare companies on the Australian market, supported by stable demand, diversified operations, and long-term industry relevance across global healthcare services. Healthcare shares continue to attract strong market attention as investors search for bus...
Here's what I expect from the beaten-down biotech stock next month. The post Should I buy CSL shares in June? appeared first on The Motley Fool Australia.
Down 40%+! I'd buy CSL and these ASX shares while investors are still cautious The Motley Fool Australia
Market caution can be frustrating, but it can also create opportunities for investors willing to look beyond the next result. The post Down 40%+! I'd buy CSL and these ASX shares while investors are still cautious appeared first on The Motley Fool Australia.
Highlights CSL remains a major healthcare player on the ASX Revenue and earnings trends continue attracting attention Financial strength remains central to long-term market confidence CSL continues to draw investor attention across the Australian share market as healthcare demand, financial performance, and business diversification strengthen its position within the [ASX 100] and broader healthcare sector. Healthcare stocks often remain firmly on investor watchlists during changing mark...
Highlights CSL Limited (ASX:CSL) operates as a constituent of the [ASX 20] with operations spanning plasma therapies, vaccines, and adjacent categories. The group maintains manufacturing and research facilities across multiple international jurisdictions including Australia, Europe, and the Americas. Operating divisions span CSL Behring, CSL Seqirus, and CSL Vifor across the broader healthcare landscape. CSL Limited operates as a global biotherapeutics company across plasma-derived therapies,...
These beaten-down ASX shares still have risks, but I think their long-term growth stories remain compelling. The post Why I'd buy DroneShield, CSL, and WiseTech shares right now appeared first on The Motley Fool Australia.
CSL shares are back below $100 after a brutal sell-off. The post Under $100, are CSL shares finally too cheap to ignore? appeared first on The Motley Fool Australia.
Can this giant produce healthy returns or is there more downside to come? The post Here are the latest growth forecasts for the CSL share price appeared first on The Motley Fool Australia.
CSL Shares Reclaim A$100 as Heavy Selling Pressure Takes Pause thebull.com.au
CSL (ASX:CSL) Shares Down Nearly 60% in a Year: Time to Consider or Avoid? Kalkine
Highlights CSL remained a major focus across the healthcare sector as market participants tracked operational momentum and sector activity. Healthcare shares continued attracting attention amid broader ASX market volatility and defensive sector rotation. Global healthcare demand and biotechnology developments remained key themes shaping sentiment across ASX 200. CSL remained closely watched across the healthcare sector as biotechnology and pharmaceutical companies continued attracting a...
Thinking of buying CSL shares? This is how you will know when it's time Market Index
This ASX healthcare giant has fallen hard, but the lower price and improving dividend appeal make it worth another look. The post Should I invest $10,000 in CSL shares before the end of May? appeared first on The Motley Fool Australia.
CSL Shares Dip To Start Week. Volume Slows Following Latest Sell-off thebull.com.au
Has the market become too pessimistic about Australia's biotech giant? The post CSL shares crash, but is a comeback looming? appeared first on The Motley Fool Australia.
Assessing CSL (ASX:CSL) Valuation After Interim CEO Review And Financial Update simplywall.st
CSL and Healius dragged the healthcare sector sharply lower this week, but EBR Systems and Blinklab still gave investors something ... Read More The post Scott Power: CSL bleeds in ‘shocking week’ for ASX healthcare stocks appeared first on Stockhead.
Scott Power: CSL bleeds in ‘shocking week’ for ASX healthcare stocks Stockhead
The safer choice may not be the one with the most upside. That is why this comparison is tricky. The post CSL shares vs CBA shares: Which is the better buy? appeared first on The Motley Fool Australia.
Highlights CSL’s dividend profile has become more noticeable following a sharp share price reset. The healthcare giant continues balancing growth ambitions with shareholder distributions. Market attention remains divided between earnings concerns and long-term healthcare demand. CSL returned to market focus after valuation weakness lifted its dividend profile while healthcare demand growth and operational recovery themes continued shaping sentiment toward the biotech giant. CSL Ltd (ASX...
Why CSL shares could be one of the best buys on the ASX right now The Motley Fool Australia
Here's what to expect over the next 12 months. The post Down 59%: Will CSL shares ever regain momentum? appeared first on The Motley Fool Australia.
Down 59%: Will CSL shares ever regain momentum? The Motley Fool Australia
Has the biotech giant switched from being a growth stock to an income stock now? Let's check. The post Is CSL now an ASX dividend stock to buy? appeared first on The Motley Fool Australia.
Is CSL now an ASX dividend stock to buy? The Motley Fool Australia
CSL (ASX:CSL) Down 44% YTD at Decade Lows: Buying Opportunity or Falling Knife? Stocks Down Under
‘True believer’ brokers split with market gloom as CSL shares slump AFR
Highlights CSL shares plunged after weaker guidance and major impairment announcements rattled market sentiment Healthcare stocks dragged the broader market lower as energy and mining sectors outperformed Investors are weighing inflation concerns, commodity strength, and global geopolitical risks CSL’s sharp decline weighed heavily on the healthcare sector while rising commodity prices supported mining and energy stocks across the australian stock market. Australian shares faced ...
Amid a renewed sell-off, healthcare analysts have pared their CSL valuations following yesterday's 'bloody' downgrade. ... Read More The post Health Check: Analysts deliver a harsh verdict on CSL appeared first on Stockhead.
The broker has been looking over the biotech giant's guidance downgrade. The post 'Blood on the Street': What is Bell Potter saying about the CSL share price crash? appeared first on The Motley Fool Australia.
Down 63%: Should you finally give up on CSL shares? The Motley Fool Australia
Highlights CSL flagged fresh impairment-related pressure across upcoming financial periods Revenue outlook reflects softer conditions in several healthcare segments Vaccine and plasma operations remain central to long-term business direction CSL outlined fresh impairment expectations alongside a softer outlook across key healthcare divisions, placing the healthcare giant under renewed market attention amid operational and sector-wide challenges. CSL Under Spotlight as Healthcare Giant R...
CSL served up a market shocker today, wiping billions off the ASX as investors piled out of healthcare and into ... Read More The post Closing Bell: CSL investors lose lunch (and arvo tea) as energy stocks bolster ASX appeared first on Stockhead.
Closing Bell: CSL investors lose lunch (and arvo tea) as energy stocks bolster ASX Stockhead
Highlights CSL faced renewed pressure after a fresh business update. Asset write-down concerns weighed heavily on sentiment. Investors continued tracking weakness across healthcare shares. CSL shares remained under pressure after the healthcare giant revised its outlook and highlighted further asset impairments, adding to concerns surrounding growth, operational performance, and long-term market confidence. CSL Faces Fresh Market Pressure as Concerns Mount Healthcare giant CSL Limited (...
CSL Shares Continue Lower as Update Adds Fuel To Bear Case: The Latest thebull.com.au
Motley Fool
Stockhead
ASX
Google News
Kalkine